D. Mutch

D. Mutch, L. Denny, M. Quinn, 2014, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

Impact of employment and insurance status on distress in gynecologic oncology patients.

D. Mutch, P. Thaker, K. Fuh, 2021, Gynecologic oncology.

Impact of an immunohistochemistry-based universal screening protocol for Lynch syndrome in endometrial cancer on genetic counseling and testing.

F. Gao, D. Mutch, P. Thaker, 2015, Gynecologic oncology.

Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence

Richard G. Moore, L. Brinton, D. Mutch, 2017, Journal of the National Cancer Institute.

Impact of the COVID-19 pandemic on referral to and delivery of gynecologic oncology care

D. Mutch, P. Thaker, K. Fuh, 2022, Gynecologic Oncology Reports.

Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer.

P. Goodfellow, K. Trinkaus, D. Mutch, 2007, Gynecologic oncology.

Factors predicting subcutaneous implanted central venous port function: the relationship between catheter tip location and port failure in patients with gynecologic malignancies.

D. Mutch, J. Rader, T. Herzog, 2001, Gynecologic oncology.

Which patients with inoperable vulvar cancer may benefit from brachytherapy in addition to external beam radiation? A Surveillance, Epidemiology, and End Results analysis.

P. Grigsby, D. Mutch, Y. Rao, 2017, Brachytherapy.

Technical Advance Expression Profiling of Mouse Endometrial Cancers Microdissected from Ethanol-Fixed, Paraffin-Embedded Tissues

P. Goodfellow, D. Mutch, O. Kabbarah, 2003 .

Long-term outcome of women who undergo panniculectomy at the time of gynecologic surgery.

Jason D. Wright, D. Mutch, J. Rader, 2006, Gynecologic oncology.

Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer.

P. Grigsby, S. Mutic, D. Mutch, 2019, International journal of radiation oncology, biology, physics.

Mapping an endometrial cancer tumor suppressor gene at 10q25 and development of a bacterial clone contig for the consensus deletion interval.

P. Goodfellow, D. Mutch, J. Rader, 1998, Genomics.

HPV Vaccines: The Second Hit to Cervical Cancer

D. Mutch, I. Zighelboim, S. Geevarghese, 2006 .

Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy

Jason D. Wright, P. Grigsby, D. Mutch, 2007, Cancer.

Advances in the Treatment of Endometrial and Ovarian Cancer

D. Mutch, 2019, Oncology & Hematology Review (US).

Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer

R. Mach, D. Mutch, D. Piwnica-Worms, 2014, Molecular Cancer.

NCCN Guidelines Insights: Cervical Cancer, Version 1.2020.

S. Bean, D. Mutch, A. Mariani, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line.

D. Mutch, T. Herzog, Jun Hua, 2005, Gynecologic oncology.

Interferon-γ and Tumor Necrosis Factor-α Induce Synergistic Cytolytic Effects in Ovarian Cancer Cell Lines—Roles of the TR60 and TR80 Tumor Necrosis Factor Receptors☆

D. Mutch, T. Herzog, E. Kost, 1999 .

Effects of radiation on TNFα-mediated cytolysis of cell lines derived from cervical carcinomas

D. Mutch, M. Kao, T. Herzog, 1992 .

Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane

D. Mutch, Yang Su, W. Hawkins, 2016, Oncotarget.

Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

Kathleen R. Cho, S. Bean, D. Mutch, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer.

P. Goodfellow, Jianhua Ruan, V. Jin, 2018, Cancer research.

Could the Genetics of Taste Affect Your Health? Lessons Learned from the Guelph Family Health Study

D. Mutch, J. Haines, E. Chamoun, 2017 .

Uterine Sarcoma, Version 1.2016: Featured Updates to the NCCN Guidelines.

Kathleen R. Cho, D. Mutch, A. Mariani, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Gynecologic Oncologists’ Perceptions of Palliative Care and Associated Barriers: A Survey of the Society of Gynecologic Oncology

D. Mutch, P. Thaker, K. Fuh, 2018, Gynecologic and Obstetric Investigation.

PTEN mutations in endometrial cancers with 10q LOH: additional evidence for the involvement of multiple tumor suppressors.

P. Goodfellow, D. Mutch, D. Gersell, 1998, Gynecologic oncology.

The role of tumor necrosis factor receptors in tumor necrosis factor-α - mediated cytolysis of ovarian cancer cell lines☆☆☆★

D. Mutch, T. Herzog, E. Kost, 1996 .

Pelvic exenteration in gynecologic oncology: a single institution study over 20 years.

D. Mutch, P. Thaker, M. Powell, 2011, Gynecologic oncology.

Two sisters with Mayer-Rokitansky-Küster-Hauser syndrome and serous adenocarcinoma of the ovary

D. Mutch, C. Chu, S. Huepenbecker, 2017, Gynecologic oncology reports.

Radiologic Assessment of Groin Lymph Nodes in Pelvic Malignancies

P. Grigsby, D. Mutch, B. Siegel, 2020, International Journal of Gynecological Cancer.

Role of Computed Axial Tomography of the Chest in Staging Patients With Nonmetastatic Gestational Trophoblastic Disease

D. Mutch, M. Baker, D. Clarke‐Pearson, 1986, Obstetrics and gynecology.

The effects of cyclosporin A on the lysis of ovarian cancer cells by cisplatin or adriamycin.

D. Mutch, T. Herzog, J. Collins, 1992 .

Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer prevention.

G. Colditz, D. Mutch, P. Thaker, 2019, Gynecologic oncology.

BRIEF COMMUNICATION FADS2 genotype influences whole-body resting fat oxidation in young adult men

D. Mutch, L. Spriet, Kaitlin Roke, 2016 .

Cyclosporin enhancement of cisplatin chemotherapy in patients with refractory gynecologic cancer. A gynecologic oncology group study

P. Disaia, D. Mutch, D. Mutch, 1994, Cancer.

Cyclosporin enhancement of cisplatin chemotherapy in patients with refractory gynecologic cancer. A Gynecologic Oncology Group Study.

D. Mutch, S. Liao, A. Manetta, 1992, Cancer.

Sarcopenia: Preoperative assessment of muscle mass to predict surgical complications and prognosis in patients with endometrial cancer

D. Mutch, P. Thaker, A. Hagemann, 2014 .

Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study

F. Gao, P. Goodfellow, L. Brinton, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers

P. Goodfellow, E. Swisher, D. Mutch, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Cervical cancer.

Kathleen R. Cho, M. Morgan, N. Dupont, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study.

D. Mutch, D. Clarke‐Pearson, J. Blessing, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability

P. Goodfellow, E. Swisher, D. Mutch, 1999, Cancer.

Divergent effects of taxol on tumor necrosis factor‐α‐mediated cytolysis of ovarian carcinoma cells

D. Mutch, J. Collins, S. Williams, 1993, American journal of obstetrics and gynecology.

Lithium Chloride and Inhibition of Glycogen Synthase Kinase 3&bgr; as a Potential Therapy for Serous Ovarian Cancer

D. M. Thompson, P. Goodfellow, D. Mutch, 2012, International Journal of Gynecologic Cancer.

SGO future forward: Our greatest challenges are our greatest opportunities.

D. Mutch, 2010, Gynecologic oncology.

The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer

D. Mutch, W. Hawkins, S. Vangveravong, 2022, BMC cancer.

Chemotherapy Response Rates Among Patients With Endometrial Cancer Who Have Elevated Serum Platelets

D. Mutch, Gongfu Zhou, P. Thaker, 2015, International Journal of Gynecologic Cancer.

Intestinal perforation in gynecologic oncology: do all patients benefit from surgical management?

D. Mutch, Gongfu Zhou, P. Thaker, 2013, Gynecologic oncology.

Gemcitabine combination chemotherapy of ovarian cancer.

D. Mutch, 2003, Gynecologic oncology.

Phase I study of rubitecan and gemcitabine in patients with advanced malignancies.

R. Govindan, D. Mutch, J. Rader, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Factors influencing residents’ interest in gynecologic oncology fellowship

D. Mutch, A. Hagemann, L. Kuroki, 2019, Gynecologic oncology reports.

Evaluation of 111 In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer

R. Wendt, D. Mutch, D. Podoloff, 2003 .

Clinical outcomes after isolated pelvic failure in cervical cancer patients treated with definitive radiation.

P. Grigsby, D. Mutch, J. Schwarz, 2019, Gynecologic oncology.

Outcomes in 24 selected patients with stage IVB cervical cancer and excellent performance status treated with radiotherapy and chemotherapy

P. Grigsby, D. Mutch, J. Rader, 2006, Radiation Medicine.

Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.

Kathleen R. Cho, S. Bean, D. Mutch, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Kathleen R. Cho, D. Mutch, A. Mariani, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study.

D. Mutch, H. Ball, S. Lentz, 1996, Gynecologic oncology.

Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer.

Jason D. Wright, F. Gao, D. Mutch, 2013, Gynecologic oncology.

Treatment of High-Risk Gestational Trophoblastic Tumors

Jason D. Wright, D. Mutch, J. Wright, 2003, Clinical obstetrics and gynecology.

In vitro analysis of the anticancer potential of tumor necrosis factor in combination with cisplatin.

D. Mutch, M. Kao, J. Collins, 1989, Gynecologic oncology.

A multi-institutional evaluation of the safety and efficacy of bevacizumab for recurrent, platinum-resistant ovarian cancer.

A. Berchuck, K. Trinkaus, D. Mutch, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recurrent gestational trophoblastic disease. Experience of the southeastern regional trophoblastic disease center

D. Mutch, D. Clarke‐Pearson, J. Soper, 1990, Cancer.

Estrogen and progesterone receptor content of endometrial carcinomas: comparison of total tissue versus cancer component analysis.

D. Mutch, K. Mccarty, W. Creasman, 1990 .

Endometrial adenocarcinoma estrogen receptor content: association of clinicopathologic features with immunohistochemical analysis compared with standard biochemical methods.

D. Mutch, K. Mccarty, W. Creasman, 1987, American journal of obstetrics and gynecology.

Long-term effects on bladder function following radical hysterectomy with and without postoperative radiation.

D. Mutch, J. Macmillan, W. Creasman, 1987, Gynecologic oncology.

Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review.

D. Mutch, A. Mariani, K. Podratz, 2008, Gynecologic oncology.

Gemcitabine in cervical cancer.

D. Mutch, J. Bloss, 2003, Gynecologic oncology.

The Dawning of the Age of Personalized Medicine in Gynecologic Oncology

D. Mutch, K. Thiel, K. Leslie, 2020, Cancers.

Uterine neoplasms, version 1.2014.

Kathleen R. Cho, N. Dupont, D. Mutch, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Epithelial Ovarian Tumors of Low Malignant Potential: The Role of Microinvasion

D. Mutch, J. Rader, T. Herzog, 2002, Obstetrics and gynecology.

Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: A review of the National Cancer Database.

P. Grigsby, D. Mutch, Y. Rao, 2017, Gynecologic oncology.

Intensity modulated radiation therapy for squamous cell carcinoma of the vulva: Treatment technique and outcomes

P. Grigsby, D. Mutch, Y. Rao, 2017, Advances in radiation oncology.

Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial.

Richard G. Moore, M. Sherman, L. Brinton, 2015, Gynecologic oncology.

Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 Trial.

Richard G. Moore, M. Sherman, L. Brinton, 2015, Journal of the National Cancer Institute.

Relationships of tubal ligation to endometrial carcinoma stage and mortality in the NRG oncology/gynecologic oncology group 210 trial

Richard G. Moore, M. Sherman, L. Brinton, 2015 .

Clear cell carcinoma of the cervix: a multi-institutional review in the post-DES era.

Jason D. Wright, D. Mutch, D. Chi, 2008, Gynecologic oncology.

Acute toxicity of postoperative IMRT and chemotherapy for endometrial cancer

P. Grigsby, D. Mutch, J. Rader, 2007, Radiation Medicine.

Carcinosarcoma of the ovary-a case series.

D. Mutch, R. Mannel, Joan L. Walker, 2006, Gynecologic oncology.

Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

D. Mutch, A. Secord, D. Miller, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Wilms’ Tumor 1 Protein and Estrogen Receptor Beta Expression are Associated with Poor Outcomes in Uterine Carcinosarcoma

F. Gao, D. Mutch, P. Thaker, 2013, Annals of Surgical Oncology.

The Utility and Management of Vaginal Cytology After Treatment for Endometrial Cancer

D. Mutch, P. Thaker, A. Hagemann, 2013, Obstetrics and gynecology.

Radical Hysterectomy for Cervical Cancer in Obese Women

E. Swisher, D. Mutch, J. Rader, 2000, Obstetrics and gynecology.

Squamous cell carcinoma of the vulva: a review of present management and future considerations

D. Mutch, T. Buchanan, 2018, Expert review of anticancer therapy.

Resistance to cytolysis by tumor necrosis factor alpha in malignant gynecological cell lines is associated with the expression of protein(s) that prevent the activation of phospholipase A2 by tumor necrosis factor alpha.

D. Mutch, M. Kao, J. Collins, 1992, Cancer research.

Utility and Cost‐Effectiveness of Preoperative Autologous Blood Donation in Gynecologic and Gynecologic Oncology Patients

D. Mutch, J. Rader, R. Gibb, 2002, Obstetrics and gynecology.

Wound Complication Rates After Vulvar Excisions for Premalignant Lesions.

D. Mutch, P. Thaker, A. Hagemann, 2019, Obstetrics and gynecology.

Modified frailty index is predictive of wound complications in obese patients undergoing gynecologic surgery via a midline vertical incision.

D. Mutch, P. Thaker, M. Powell, 2020, Gynecologic oncology.

Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer?

D. Mutch, N. Horowitz, D. Cohn, 2003, Gynecologic oncology.

Analysis of MSH3 in Endometrial Cancers With Defective DNA Mismatch Repair

P. Goodfellow, E. Swisher, D. Mutch, 1998, The Journal of the Society for Gynecologic Investigation: JSGI.

Excess of early onset multiple myeloma in endometrial cancer probands and their relatives suggests common susceptibility.

P. Goodfellow, D. Mutch, M. Powell, 2007, Gynecologic oncology.

Evaluation of the family history collection process and the accuracy of cancer reporting among a series of women with endometrial cancer.

J. Ivanovich, P. Goodfellow, D. Mutch, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clustering of Lynch syndrome malignancies with no evidence for a role of DNA mismatch repair.

S. Thibodeau, P. Goodfellow, D. Mutch, 2008, Gynecologic oncology.

Corpus Uteri – Sarcoma

B. Erickson, E. Oliva, D. Mutch, 2017 .

Familial peripartum cardiomyopathy after molar pregnancy

D. Mutch, L. Massad, Craig K. Reiss, 1993, Obstetrics and gynecology.

Should we abandon minimally invasive surgery for cervical cancer ?

D. Mutch, M. Mullen, 2019 .

FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival.

P. Grigsby, D. Mutch, B. Siegel, 2020, Gynecologic oncology.

Management and prognosis of cervical cancer patients treated with definitive radiation therapy who have partial metabolic response on post-therapy positron emission tomography.

P. Grigsby, D. Mutch, B. Siegel, 2022, Gynecologic oncology.

Morbidity of Cytoreductive Surgery in the Elderly

Jason D. Wright, D. Mutch, J. Rader, 2003, American journal of obstetrics and gynecology.

Endometrial Cancer: Histologic Correlates of Immunohistochemical Localization of Progesterone Receptor and Estrogen Receptor

D. Mutch, K. Mccarty, W. Creasman, 1989, Obstetrics and gynecology.

Targeted Diagnostic Agent for Ovarian Cancer: Initial Clinical Results

R. Wendt, D. Mutch, D. Podoloff, 2003 .

Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines

D. Mutch, J. Rader, T. Herzog, 1994, Cancer.

Divergent effects of taxol on tumor necrosis factor-α-mediated cytolysis of ovarian carcinoma cells

D. Mutch, Ling Xu, J. Collins, 1992 .

Incorporation of Porcine Adenovirus 4 Fiber Protein Enhances Infectivity of Adenovirus Vector on Dendritic Cells: Implications for Immune-Mediated Cancer Therapy

D. Mutch, M. Colonna, D. Curiel, 2014, PloS one.

A fellow-run clinic achieves similar patient outcomes as faculty clinics: A safe and feasible model for gynecologic oncology fellow education.

D. Mutch, P. Thaker, K. Fuh, 2020, Gynecologic oncology.

Premature Judgment of Uterine Morcellation: Look at the Data Before You Leap.

D. Mutch, 2015, Journal of the National Cancer Institute.

Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer.

P. Grigsby, D. Mutch, J. Rader, 2009, Gynecologic Oncology.

Long-Term Outcomes of Cervical Cancer Patients Treated With Definitive Chemoradiation Following a Complete Metabolic Response.

P. Grigsby, D. Mutch, B. Siegel, 2021, Clinical oncology (Royal College of Radiologists (Great Britain)).

Small‐Cell Undifferentiated Carcinoma of the Cervix: A Clinicopathologic, Ultrastructural, and Immunocytochemical Study of 15 Cases

D. Mutch, D. Gersell, G. Mazoujian, 1988, The American journal of surgical pathology.

Cervical cancer: Clinical practice guidelines in oncology

Kathleen R. Cho, M. Morgan, N. Dupont, 2013 .

Growth modulatory effects of granulocyte-macrophage colony-stimulating factor on human cell lines derived from gynecologic malignancies.

D. Mutch, H. Camel, T. Herzog, 1996, American journal of obstetrics and gynecology.

Effects of cancer treatment on ovarian function.

P. Grigsby, D. Mutch, J. Rader, 2009, Fertility and sterility.

The Role of Surgery 16

D. Mutch, J. Soper, C. Hammond, 1987 .

The Role of Surgery

D. Mutch, J. Soper, C. Hammond, 1987 .

the mouse intestinal tract Regional variations in ABC transporter expression along

W. Wahli, D. Mutch, M. Roberts, 2013 .

Discussion: 'Accuracy of preoperative endometrial sampling' by Huang et al.

D. Mutch, J. Allsworth, M. Powell, 2007, American journal of obstetrics and gynecology.

An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.

R. Burger, M. Birrer, D. Mutch, 2017, Gynecologic oncology.

Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody.

D. Mutch, J. Flowers, K. Mccarty, 1986, Cancer research.

Retrorectal Tumors: A Diagnostic and Therapeutic Challenge

J. Fleshman, D. Mutch, S. Glasgow, 2005, Diseases of the colon and rectum.

Expression profiling of mouse endometrial cancers microdissected from ethanol-fixed, paraffin-embedded tissues.

P. Goodfellow, D. Mutch, O. Kabbarah, 2003, The American journal of pathology.

Cervical sarcomas: an analysis of incidence and outcome.

Jason D. Wright, D. Mutch, J. Rader, 2005, Gynecologic oncology.

Biology of Epithelial Ovarian Cancer

D. Mutch, Sybilann Williams, 1994, Clinical obstetrics and gynecology.

Patterns of CTCF and ZFHX3 Mutation and Associated Outcomes in Endometrial Cancer.

K. Coombes, P. Goodfellow, R. Bundschuh, 2015, Journal of the National Cancer Institute.

DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis

P. Goodfellow, D. Mutch, J. Rader, 2006, Modern Pathology.

Aberrant Methylation of the X-Linked Ribosomal S6 Kinase RPS6KA6 (RSK4) in Endometrial Cancers

F. Gao, D. M. Thompson, P. Goodfellow, 2011, Clinical Cancer Research.

New therapies for advanced, recurrent, and metastatic endometrial cancers

R. Wenham, D. Mutch, D. Miller, 2017, Gynecologic Oncology Research and Practice.

2 Genome-Wide Approaches

K. Clément, D. Mutch, J. Hager, 2007 .

Microscaled proteogenomic methods for precision oncology

S. Carr, D. Chan, Purba Singh, 2019, Nature Communications.

Hereditary Ovarian Cancer and Risk Reduction.

L. Andrews, D. Mutch, 2017, Best practice & research. Clinical obstetrics & gynaecology.

An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.

D. Tritchler, P. Goodfellow, D. Mutch, 2018, Gynecologic oncology.

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

James X. Sun, A. Oza, D. Provencher, 2017, The Lancet.

10 and Replication Errors in Endometrical Cancers Allelic Loss of Sequences from the Long Arm of Chromosome Updated

P. Goodfellow, D. Mutch, T. Herzog, 2006 .

The homozygous complete hydatidiform mole: a unique resource for genome studies.

P. Kwok, L. Hillier, P. Taillon-Miller, 1997, Genomics.

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

D. Alberts, R. Burger, E. Trimble, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer

D. Mutch, E. Rankin, P. Thaker, 2016, Oncotarget.

Pathology of cancers of the female genital tract including molecular pathology

D. Mutch, J. Prat, 2018, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

Opposing effects of cancer type-specific SPOP mutations on BET protein degradation and sensitivity to BET inhibitors

S. Carr, L. Garraway, M. Peter, 2017, Nature Medicine.

Chapter 20 – Genes and Cancer

P. Disaia, D. Mutch, 2007 .

RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers.

P. Goodfellow, D. Mutch, M. A. Mallon, 2004, American journal of obstetrics and gynecology.

Chapter 16 – Molecular Genetics of Endometrial Cancers

P. Goodfellow, D. Mutch, 2004 .

Clinical significance of microsatellite instability in endometrial carcinoma

P. Goodfellow, D. Mutch, J. Rader, 2000, Cancer.

Mutational analysis of the PMS2 gene in sporadic endometrial cancers with microsatellite instability.

P. Goodfellow, E. Swisher, D. Mutch, 1999, Gynecologic oncology.

Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer.

Jingqin Luo, Daniel E Deatherage, Daniel E. Deatherage, 2009, Cancer research.

Cervical cancer, version 2.2015: Featured updates to the NCCN guidelines featured updates to the NCCN guidelines

Kathleen R. Cho, D. Mutch, Nicole R. McMillian, 2015 .

Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma12

D. Mutch, Daofeng Li, Ting Wang, 2017, Neoplasia.

A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer.

Zhihui Feng, Issam M El Naqa, Xiaowei Wang, 2009, Gynecologic oncology.

2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer.

Jaime Prat, D. Mutch, J. Prat, 2014, Gynecologic oncology.

Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study.

Christopher I Amos, C. Amos, D. Mutch, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Disparities in ovarian cancer care quality and survival according to race and socioeconomic status.

P. Roland, D. Mutch, W. Cliby, 2013, Journal of the National Cancer Institute.

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.

D. Levine, D. Mutch, A. Secord, 2021, Gynecologic oncology.

Paternal origins of complete hydatidiform moles proven by whole genome single-nucleotide polymorphism haplotyping.

Pui-Yan Kwok, Urvashi Surti, Jian-Bing Fan, 2002, Genomics.

Low yield of residual vulvar carcinoma and dysplasia upon re-excision for close or positive margins.

D. Mutch, P. Thaker, A. Hagemann, 2013, Gynecologic oncology.

Novel SOX17 frameshift mutations in endometrial cancer are functionally distinct from recurrent missense mutations

P. Goodfellow, D. Mutch, D. Cohn, 2017, Oncotarget.

Promoter Hypomethylation of EpCAM-Regulated Bone Morphogenetic Protein Gene Family in Recurrent Endometrial Cancer

I. Thompson, P. Goodfellow, Jianhua Ruan, 2013, Clinical Cancer Research.

Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas.

Jingqin Luo, P. Goodfellow, D. Mutch, 2010, Gynecologic oncology.

Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history.

P. Goodfellow, D. Mutch, J. Rader, 2004, American journal of human genetics.

Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.

D. Mutch, Austin Miller, N. Horowitz, 2018, Gynecologic oncology.

Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.

P J Eifel, P. Grigsby, D. Mutch, 1999, The New England journal of medicine.

Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer

D. Mutch, P. Thaker, K. Fuh, 2018, Molecular Cancer Therapeutics.

Practice Bulletin No. 53—Diagnosis and Treatment of Gestational Trophoblastic Disease

D. Mutch, Joan L. Walker, J. Soper, 2004 .

CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.

D. Mutch, J. Rader, R. Gibb, 2006, Gynecologic oncology.

Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.

Mitchell Morris, Patricia J Eifel, P. Grigsby, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Utility of Peritoneal Biopsy and Omentectomy in the Upstaging of Apparent Early Ovarian Cancer

D. Mutch, P. Thaker, M. Powell, 2011, International Journal of Gynecologic Cancer.

Irradiation alone or combined with surgery in stage IB, IIA, and IIB carcinoma of uterine cervix: update of a nonrandomized comparison.

P. Grigsby, D. Mutch, C. Perez, 1995, International journal of radiation oncology, biology, physics.

Tumor Lysis Syndrome in a Patient With Metastatic Endometrial Cancer Treated With Lattice Stereotactic Body Radiation Therapy

D. Mutch, C. Robinson, J. Kavanaugh, 2021, Advances in radiation oncology.

Phase I Study and Preliminary Pharmacology of the Novel Innate Immune Modulator rBBX-01 in Gynecologic Cancers

D. Mutch, J. Rader, N. Dimitrov, 2008, Clinical Cancer Research.

FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features

P. Pollock, S. Byron, P. Goodfellow, 2012, PloS one.

Frequent mutations in the RPL22 gene and its clinical and functional implications.

P. Goodfellow, D. Mutch, M. Powell, 2013, Gynecologic oncology.

NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021.

D. Mutch, A. Mariani, S. George, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Factors affecting long-term outcome of irradiation in carcinoma of the vagina.

P. Grigsby, D. Mutch, C. Perez, 1999, International journal of radiation oncology, biology, physics.

Paraganglioma of the vagina: report of a case, including immunohistochemical and ultrastructural findings.

L. Ylagan, D. Mutch, S. Bhalla, 2003, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer

M. Washington, D. Mutch, T. Baker, 2021, CA: a cancer journal for clinicians.

Long-term assessment of bladder and bowel dysfunction after radical hysterectomy.

D. Mutch, J. Rader, L. Wall, 2009, Gynecologic oncology.

Frequent deletion of chromosome 1p sequences in an aggressive histologic subtype of endometrial cancer.

P. Goodfellow, D. Mutch, T. Herzog, 1996, Human molecular genetics.

Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers.

P. Goodfellow, D. Mutch, T. Herzog, 1995, Cancer research.

Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259)

Michael B. Spring, S. Sereika, D. Mutch, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene therapy in gynecological cancer

D. Mutch, R. Brooks, 2006, Expert review of anticancer therapy.

MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers.

J. Palazzo, P. Goodfellow, E. Swisher, 1999, Human molecular genetics.

Phosphatase and tensin homolog (PTEN) pseudogene expression in endometrial cancer: a conserved regulatory mechanism important in tumorigenesis?

P. Goodfellow, D. Mutch, Katherine B. Chiappinelli, 2011, Gynecologic oncology.

A multi-institutional review of outcomes of endometrial stromal sarcoma.

D. Mutch, P. Argenta, M. Geller, 2007, Gynecologic oncology.

Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study.

D. Mutch, T. Herzog, C. Tian, 2008, Gynecologic oncology.

Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.

D. Mutch, J. Rader, R. Gibb, 2006, Gynecologic oncology.

GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study.

P. Goodfellow, M. Birrer, D. Mutch, 2019, Gynecologic oncology.

Evidence for heritable predisposition to epigenetic silencing of MLH1

P. Goodfellow, D. Mutch, A. Chapelle, 2007, International journal of cancer.

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials

E. Kohn, H. Mackay, J. McAlpine, 2017, Oncotarget.

Cervical Cancer, Version 2.2015.

R Kevin Reynolds, Kathleen R. Cho, Peter Frederick, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Characterization of the homeodomain gene EMX2: sequence conservation, expression analysis, and a search for mutations in endometrial cancers.

P. Goodfellow, D. Mutch, F. Noonan, 2001, Genomics.

Absence of PTEN repeat tract mutation in endometrial cancers with microsatellite instability.

P. Goodfellow, D. Mutch, J. Rader, 2000, Gynecologic oncology.

Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience

D. Mutch, A. Mariani, L. Havrilesky, 2006, International Journal of Gynecologic Cancer.

Atypical clustering of gynecologic malignancies: A family study including molecular analysis of candidate genes.

P. Goodfellow, D. Mutch, J. Rader, 2000, Gynecologic oncology.

Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer.

D. Mutch, Y. Yoshioka, E. Morii, 2011, Gynecologic oncology.

The promise of molecular staging for the future

D. Mutch, G. Maxwell, 2017, Cancer.

Use of mutation profiles to refine the classification of endometrial carcinomas

Thomas Zeng, Martin Hirst, Kane Tse, 2012, The Journal of pathology.

Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type.

P. Goodfellow, D. Mutch, J. Rader, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer.

P. Goodfellow, E. Hade, D. Mutch, 2016, Gynecologic oncology.

Effect of a T0 radical hysterectomy specimen on survival for early stage cervical cancer.

P. Grigsby, D. Mutch, J. Rader, 2007, Gynecologic oncology.

Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

M. Birrer, D. Mutch, D. Miller, 2019, Gynecologic oncology.

Targeted Endometrial Cancer Therapy as a Future Prospect

D. Mutch, C. Cheewakriangkrai, D. Thanapprapasr, 2013, Women's health.

Cervix carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence.

P. Grigsby, Anurag K. Singh, D. Mutch, 2005, International journal of radiation oncology, biology, physics.

Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.

D. Mutch, A. Mariani, Nicole R. McMillian, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Preoperative lymph node staging of early‐stage cervical carcinoma by [18F]‐fluoro‐2‐deoxy‐D‐glucose–positron emission tomography

P. Grigsby, D. Mutch, J. Rader, 2005, Cancer.

Update on Prognostic Markers for Endometrial Cancer

D. Mutch, P. Binder, 2014, Women's health.

SOX11 hypermethylation as a tumor biomarker in endometrial cancer.

D. Mutch, J. Rader, T. Huang, 2019, Biochimie.

Bioactive antibiotic levels in the human aorta.

D. Mutch, D. Mulder, G. Richards, 1982, Surgery.

Continuous epidural infusion in gynecologic oncology patients undergoing exploratory laparotomy: The new standard for decreased postoperative pain and opioid use.

D. Mutch, P. Thaker, D. Helsten, 2019, Gynecologic oncology.

The significance of pneumatosis intestinalis or bowel perforation in patients with gynecologic malignancies.

D. Mutch, J. Rader, R. Gibb, 2002, Gynecologic oncology.

Ovarian cancer in the United States: contemporary patterns of care associated with improved survival.

P. Roland, D. Mutch, W. Cliby, 2015, Gynecologic oncology.

Correlates of length of stay in gynecologic oncology patients undergoing inpatient surgery.

D. Mutch, T. Herzog, G. Vogler, 1993, Gynecologic oncology.

Molecular staging of gynecological cancer: What is the future?

D. Mutch, J. Prat, P. Binder, 2015, Best practice & research. Clinical obstetrics & gynaecology.

Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.

B. Karlan, A. Berchuck, J. Lancaster, 2007, Gynecologic oncology.

ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.

S. Gruber, B. Karlan, A. Berchuck, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes

Kenneth Offit, David G. Mutch, Stephen Gruber, 2006, Annals of Surgical Oncology.

Nutritional Genomics in Obesity Prevention and Treatment

D. Mutch, M. Bakovic, Branden R. Deschambault, 2010 .

The Role of Genetic Testing for Cancer Susceptibility in Gynecologic Practice

B. Karlan, A. Berchuck, D. Mutch, 2007, Obstetrics and gynecology.

Gynecologic Manifestations of Hereditary Nonpolyposis Colorectal Cancer

D. Mutch, Nicholas P. Taylor, 2006 .

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

D. Mutch, A. Secord, M. Orlando, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing

David G. Mutch, Robi D. Mitra, R. Mitra, 2009, Nucleic acids research.

Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET.

P. Grigsby, D. Mutch, J. Rader, 2005, International journal of radiation oncology, biology, physics.

Posttherapy surveillance monitoring of cervical cancer by FDG-PET.

P. Grigsby, D. Mutch, B. Siegel, 2003, International journal of radiation oncology, biology, physics.

Irradiation in carcinoma of the vulva: factors affecting outcome.

P. Grigsby, D. Mutch, C. Perez, 1998, International journal of radiation oncology, biology, physics.

Cancer Among First‐degree Relatives of Probands With Invasive and Borderline Ovarian Cancer

D. Mutch, J. Rader, R. Neuman, 1998, Obstetrics and gynecology.

Uterine Serous Carcinoma: Increased Familial Risk for Lynch-Associated Malignancies

P. Goodfellow, L. Brinton, D. Mutch, 2012, Cancer Prevention Research.

Cervical Dysplasia in Adolescents

D. Mutch, J. Rader, R. Gibb, 2005, Obstetrics and gynecology.

Elevated White Blood Cell Count at the Time of Recurrence Diagnosis Is an Indicator of Short Survival in Patients With Recurrent Cervical Cancer

D. Mutch, S. Mabuchi, T. Hamasaki, 2012, International Journal of Gynecologic Cancer.

Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer.

P. Goodfellow, D. Mutch, P. Thaker, 2012, Gynecologic oncology.

MLH3 mutation in endometrial cancer.

S. Thibodeau, P. Goodfellow, D. Mutch, 2006, Cancer research.

Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer

A. Dietz, D. Mutch, D. Curiel, 2017, PloS one.

Identifying regulatory hubs in obesity with nutrigenomics

D. Mutch, 2006 .

Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study.

J. Miecznikowski, J. Gonzalez-Bosquet, M. Birrer, 2017, Gynecologic oncology.

Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis

P. Goodfellow, E. Hade, D. Mutch, 2016, International Journal of Gynecologic Cancer.

Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: A 6 year follow-up study.

D. Mutch, P. Thaker, M. Powell, 2019, Gynecologic oncology.

Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.

R. Wenham, D. Mutch, D. Bodurka, 2018, Gynecologic oncology.

Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma.

D. Gerhard, K. Trinkaus, D. Mutch, 2005, Gynecologic oncology.

Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors.

D. Mutch, J. Rader, P. Thaker, 2010, Gynecologic oncology.

Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.

M. Birrer, D. Mutch, M. Quinn, 2017, Gynecologic oncology.

Neoadjuvant Chemotherapy Versus Primary Cytoreductive Surgery for Stage IV Uterine Serous Carcinoma

D. Mutch, P. Thaker, A. Hagemann, 2015, International Journal of Gynecologic Cancer.

Wound complications after gynecologic cancer surgery.

D. Mutch, P. Thaker, F. Gao, 2011, Gynecologic oncology.

Cervical carcinoma in the elderly

P. Grigsby, K. Trinkaus, D. Mutch, 2005, Cancer.

A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

D. Mutch, D. Miller, K. Leslie, 2014, Gynecologic oncology.

The clinical management of inoperable endometrial carcinoma

D. Mutch, M. Palisoul, 2016, Expert review of anticancer therapy.

Management of Endometrial Cancer

D. Mutch, W. Fowler, 2008, Women's health.

Brachytherapy Is Associated With Improved Survival in Inoperable Stage I Endometrial Adenocarcinoma: A Population-Based Analysis.

P. Grigsby, D. Mutch, J. Schwarz, 2015, International journal of radiation oncology, biology, physics.

Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer.

P. Grigsby, D. Mutch, M. Powell, 2005, International journal of radiation oncology, biology, physics.

Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer.

P. Grigsby, D. Mutch, J. Rader, 2004, Gynecologic oncology.

Adjuvant radiotherapy in Stage II endometrial carcinoma: Is brachytherapy alone sufficient for local control?

P. Grigsby, D. Mutch, J. Schwarz, 2015, Brachytherapy.

Wound Complication Rates After Staples or Suture for Midline Vertical Skin Closure in Obese Women: A Randomized Controlled Trial.

D. Mutch, P. Thaker, A. Hagemann, 2017, Obstetrics and gynecology.

A phase II trial of a surgical protocol to decrease the incidence of wound complications in obese gynecologic oncology patients.

D. Mutch, P. Thaker, A. Hagemann, 2014, Gynecologic oncology.

Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis.

P. Grigsby, D. Mutch, J. Rader, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q).

D. Mutch, M. Shahin, T. Herzog, 2011, Gynecologic oncology.

FDG-PET evaluation of vaginal carcinoma.

P. Grigsby, D. Mutch, J. Rader, 2005, International journal of radiation oncology, biology, physics.

A novel algorithm for network-based prediction of cancer recurrence.

Jianhua Ruan, Chengwei Lei, Md. Jamiul Jahid, 2016, Genomics.

Network-based classification of recurrent endometrial cancers using high-throughput DNA methylation data

Tim Hui-Ming Huang, Fei Gu, Jianhua Ruan, 2012, BCB.

Differential Methylation Hybridization Array of Endometrial Cancers

P. Goodfellow, D. Mutch, T. Huang, 2007 .

Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancer

D. Mutch, P. Thaker, K. Fuh, 2021, Gynecologic oncology reports.

Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer.

Sasa Mutic, Matthew A Powell, Farrokh Dehdashti, 2010, International journal of radiation oncology, biology, physics.

Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma.

P. Goodfellow, D. Mutch, J. Rader, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Frequent HOXA 11 and THBS 2 Promoter Methylation , and a Methylator Phenotype in Endometrial Adenocarcinoma 1

P. Goodfellow, D. Mutch, J. Rader, 2003 .

CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer.

P. Grigsby, D. Gerhard, I. Borecki, 2007, Cancer research.

CD 83 Gene Polymorphisms Increase Susceptibility to Human Invasive Cervical Cancer

P. Grigsby, D. Gerhard, I. Borecki, 2007 .

A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)

D. Mutch, P. Fracasso, P. Thaker, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

D. Mutch, U. Matulonis, C. Aghajanian, 2019, Gynecologic oncology.

Malignant melanoma of the vulva: an extension of cutaneous melanoma?

D. Mutch, D. Chi, K. Moxley, 2011, Gynecologic oncology.

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.

E. Petricoin, D. Matei, M. Birrer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization

Jonathan W. Song, P. Goodfellow, D. Mutch, 2018, Journal of the National Cancer Institute.

Common expression of a tumor necrosis factor resistance mechanism among gynecological malignancies

D. Mutch, M. Kao, J. Collins, 2005, Cancer Immunology, Immunotherapy.

Proliferative and antiproliferative effects of interferon-'Y and tumor necrosis factor-α. on cell lines derived from cervical and ovarian malignancies

D. Mutch, M. Kao, J. Collins, 1990 .

Clinical and Pathologic Features of Vulvar Intraepithelial Neoplasia in Premenopausal and Postmenopausal Women

D. Mutch, C. Barr, A. Case, 2011, Journal of lower genital tract disease.

Do gynecologic oncology patients with severely diminished renal function and urinary tract obstruction benefit from ureteral stenting or percutaneous nephrostomy?

D. Mutch, P. Thaker, K. Fuh, 2019, Gynecologic oncology reports.

The clinical implications of hydronephrosis and the level of ureteral obstruction in stage IIIB cervical cancer.

P. Grigsby, D. Mutch, K. Chao, 1998, International journal of radiation oncology, biology, physics.

Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors

D. Mutch, J. Wheler, A. Traynor, 2017, The oncologist.

Erratum: Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology

D. Mutch, D. Curiel, I. Dmitriev, 2016, Scientific Reports.

Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology

D. Mutch, D. Curiel, I. Dmitriev, 2016, Scientific Reports.

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report.

E. Kohn, H. Mackay, D. Mutch, 2018, Gynecologic oncology.

Bevacizumab combination therapy in recurrent, platinum‐refractory, epithelial ovarian carcinoma

D. Mutch, J. Rader, R. Gibb, 2006, Cancer.

ACOG Practice Bulletin, clinical management guidelines for obstetrician-gynecologists number 98, October 2008 (replaces Practice Bulletin number 58, December 2004). Ultrasonography in pregnancy.

D. Mutch, J. Soper, J. Schink, 2008, Obstetrics and gynecology.

Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix.

P. Grigsby, D. Mutch, K. Chao, 1998, International journal of radiation oncology, biology, physics.

IRRADIATION ALONE OR COMBINED WITH SURGERY IN STAGE IIB CARCINOMA OF UTERINE CERVIX: UPDATE OF A NONRANDOMIZED COMPARISON IB, IIA, AND

P. Grigsby, D. Mutch, C. Perez, 1995 .

Postradiation Damage to the Pelvic Girdle in Cervical Cancer Patients: Is Intensity-Modulated Radiation Therapy Safer Than Conventional Radiation?

D. Mutch, Gongfu Zhou, P. Thaker, 2014, International Journal of Gynecologic Cancer.

Low Allele Frequency of MLH1 D132H in American Colorectal and Endometrial Cancer Patients

S. Gruber, G. Rennert, P. Goodfellow, 2005, Diseases of the colon and rectum.

Antisense transcripts at the EMX2 locus in human and mouse.

P. Goodfellow, D. Mutch, T. C. Simon, 2003, Genomics.

A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial.

W. Richards, D. Mutch, A. Secord, 2019, Journal of Clinical Oncology.

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

D. Mutch, R. Reynolds, N. Teng, 2012 .

Absence of MGMT promoter methylation in endometrial cancer.

P. Goodfellow, D. Mutch, M. Powell, 2009, Gynecologic oncology.

ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes.

Matthew A Powell, Feng Gao, P. Goodfellow, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surgical management of ovarian cancer.

D. Mutch, 2002, Seminars in oncology.

GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress

D. Mutch, E. Rankin, P. Thaker, 2021, Molecular Cancer Research.

Prophylactic oophorectomy and ovarian cancer surveillance. Patient perceptions and satisfaction.

E. Swisher, D. Mutch, J. Rader, 2001, The Journal of reproductive medicine.

Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer.

P. Grigsby, D. Mutch, J. Rader, 2009, Gynecologic oncology.

The more things change the more they stay the same.

D. Mutch, 2012, Gynecologic oncology.

Ovarian cancer: to screen or not to screen.

D. Mutch, 2009, Obstetrics and gynecology.

Association between body mass index and surgical menopausal symptoms in patients with early stage endometrial cancer.

D. Mutch, P. Thaker, K. Fuh, 2019, Gynecologic oncology.

Qualitative Evaluation of Medical Information Processing Needs of 60 Women Choosing Ovarian Cancer Surveillance or Prophylactic Oophorectomy

E. Swisher, D. Mutch, J. Rader, 2002, Journal of Genetic Counseling.

Treatment Strategies and Prognosis of Endometrial Cancer

D. Mutch, G. Garg, 2012 .

Bethesda System 2001

M. Bibbo, L. Ylagan, P. Abbitt, 2001, Acta Cytologica.

The mutational spectrum of FOXA2 in endometrioid endometrial cancer points to a tumor suppressor role.

P. Goodfellow, D. Mutch, D. Cohn, 2016, Gynecologic oncology.

The effect of a multidisciplinary palliative care initiative on end of life care in gynecologic oncology patients.

D. Mutch, P. Thaker, A. Hagemann, 2017, Gynecologic oncology.

Resource utilization for ovarian cancer patients at the end of life: how much is too much?

D. Mutch, J. Rader, R. Gibb, 2005, Gynecologic oncology.

Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.

R. Burger, R. Wenham, D. Mutch, 2019, Obstetrics and gynecology.

Increased Risk for Hereditary Nonpolyposis Colorectal Cancer-Associated Synchronous and Metachronous Malignancies in Patients with Microsatellite Instability-Positive Endometrial Carcinoma Lacking MLH1 Promoter Methylation

P. Goodfellow, D. Mutch, J. Rader, 2004, Clinical Cancer Research.

Targeted metabolomic profiling of low and high grade serous epithelial ovarian cancer tissues: a pilot study

D. Mutch, B. Rosen, A. Yilmaz, 2018, Metabolomics.

Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

K. Robison, P. Goodfellow, D. Mutch, 2015, Gynecologic oncology.

External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer.

P. Grigsby, D. Mutch, J. Rader, 2007, Gynecologic oncology.

Endometrial Adenocarcinoma Using a Monoclonal Antibody Immunohistochemical Analyses of Estrogen Receptor in Updated

D. Mutch, J. Flowers, K. Mccarty, 2006 .

A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer

A. Berchuck, K. Trinkaus, D. Mutch, 2007, International Journal of Gynecologic Cancer.

Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy

D. Mutch, S. Bhoola, W. Huh, 2005 .

Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy.

P. Grigsby, D. Mutch, P. Thaker, 2016, Gynecologic oncology.

Use of complementary and alternative medicine among women with gynecologic cancers.

E. Swisher, D. Mutch, J. Rader, 2002, Gynecologic oncology.

Inhibition of protein synthesis enhances the lytic effects of tumor necrosis factor α and interferon γ in cell lines derived from gynecological malignancies

D. Mutch, M. Kao, J. Collins, 2005, Cancer Immunology, Immunotherapy.

Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer

D. Mutch, P. Thaker, K. Fuh, 2021, Cancers.

The emerging role of precision medicine in the treatment of endometrial cancer

D. Mutch, M. Toboni, 2020 .

Inpatient management of hypercalcemia portends a poor prognosis among gynecologic oncology patients: A trigger to initiate hospice care?

D. Mutch, P. Thaker, K. Fuh, 2019, Gynecologic oncology reports.

SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth.

D. Mutch, C. Starks, P. Thaker, 2018, Gynecologic oncology.

Ability of visual tests to predict underlying cervical neoplasia. Colposcopy and speculoscopy.

D. Mutch, N. Lonky, L. Massad, 1995, The Journal of reproductive medicine.

Metastatic seeding of a percutaneous nephrostomy tract causing cervical carcinoma.

D. Mutch, M. Darcy, E. S. Shin, 2002, AJR. American journal of roentgenology.

Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study

L. Brinton, D. Mutch, L. Downs, 2018, International journal of cancer.

WITH FLUORODEOXYGLUCOSE – POSITRON EMISSION TOMOGRAPHY SIMULATION IN PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER

P. Grigsby, S. Mutic, D. Mutch, 2022 .

Estrogen and progesterone receptor content of endometrial carcinomas: Comparison of total tissue versus cancer component analysis

D. Mutch, J. Soper, W. Creasman, 1991, Gynecologic Oncology.

Timing of Referral for Genetic Counseling and Genetic Testing in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

D. Jeffe, D. Mutch, P. Thaker, 2013, International Journal of Gynecologic Cancer.

Inferior vena cava filter placement in the gynecologic oncology patient: A 15-year institutional experience.

D. Mutch, S. Vedantham, N. Saad, 2011, Gynecologic oncology.

Disclosing a Diagnosis of Cancer: Considerations Specific to Gynecologic Oncology Patients

D. Jeffe, D. Mutch, P. Thaker, 2013, Obstetrics and gynecology.

Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer

P. Grigsby, D. Mutch, P. Thaker, 2020, International Journal of Gynecological Cancer.

Radiation therapy for carcinoma of the cervix with biopsy-proven positive para-aortic lymph nodes.

P. Grigsby, D. Mutch, J. Rader, 2001, International journal of radiation oncology, biology, physics.

Human Papillomavirus Triage for Young Women With Atypical Squamous Cells of Undetermined Significance

D. Mutch, J. Rader, R. Gibb, 2006, Obstetrics and gynecology.

Improving Psychological Adjustment Among Late-Stage Ovarian Cancer Patients: Examining the Role of Avoidance in Treatment

Ann D. Rost, K. Wilson, D. Mutch, 2012 .

Lymphnode staging update in the American Joint Committee on Cancer 8th Edition cancer staging manual.

David G. Mutch, D. Mutch, A. Olawaiye, 2018, Gynecologic oncology.

Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.

D. Mutch, J. Rader, P. Thaker, 2010, Gynecologic oncology.

The future role of molecular staging in gynecologic cancer

D. Mutch, J. Prat, P. Binder, 2015, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.

Meenakshi Singh, D. Mutch, A. Secord, 2021, Gynecologic oncology.

Use of speculoscopy in the evaluation of women with atypical Papanicolaou smears. Improved cost effectiveness by selective colposcopy.

D. Mutch, W J Mann, N. Lonky, 1993, The Journal of reproductive medicine.

Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.

D. Mutch, J. Rader, R. Gibb, 2008, Gynecologic oncology.

Defective DNA mismatch repair and XRCC2 mutation in uterine carcinosarcomas.

P. Goodfellow, D. Mutch, R. Gibb, 2006, Gynecologic oncology.

Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer

P. Grigsby, Xiaowei Wang, D. Mutch, 2017, British Journal of Cancer.

Diagnosis and Management of Precancerous Cervical Lesions

D. Mutch, M. Auer, 2014, Current Obstetrics and Gynecology Reports.

Novel cytotoxic agents from an unexpected source: bile acids and ovarian tumor apoptosis.

D. Mutch, R. Gibb, T. Herzog, 2007, Gynecologic oncology.

Ovarian cancer patient surveillance after curative-intent initial treatment.

D. Mutch, R. Gibb, Katherine S. Virgo, 2011, Gynecologic oncology.

GAS6-AXL inhibition by AVB-500 overcomes resistance to paclitaxel in endometrial cancer by decreasing tumor cell glycolysis.

D. Mutch, P. Thaker, K. Fuh, 2022, Molecular cancer therapeutics.

Can molecular diagnostics usher in a new era for screening, diagnosis, and treatment of ovarian cancer?

D. Mutch, 2014, Obstetrics and gynecology.

Survival of Cervical Cancer Patients Presenting with Occult Supraclavicular Metastases Detected by FDG-Positron Emission Tomography/CT: Impact of Disease Extent and Treatment

P. Grigsby, D. Mutch, P. Thaker, 2017, Gynecologic and Obstetric Investigation.

In vitro chemoresponse to cisplatin and outcomes in cervical cancer.

P. Grigsby, D. Mutch, J. Schwarz, 2013, Gynecologic Oncology.

Relationship of ovarian neoplasms and body mass index.

D. Mutch, J. Rader, R. Gibb, 2005, Journal of reproductive medicine.

Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage uterine carcinosarcoma: a population-based analysis.

D. Mutch, K. Schwartz, M. Powell, 2014, Gynecologic oncology.

"Surgical Apgar Score" predicts postoperative complications after cytoreduction for advanced ovarian cancer.

Matthew A Powell, Feng Gao, D. Mutch, 2010, Gynecologic oncology.

Racial Disparities in Uterine Clear Cell Carcinoma: A Multi-Institution Study

D. Mutch, S. Dowdy, A. Munkarah, 2014, International Journal of Gynecologic Cancer.

Evaluation of Ovarian Cancer: Initial Application of Coregistered Photoacoustic Tomography and US.

Quing Zhu, Atahar Mostafa, Cary Siegel, 2018, Radiology.

p5RHH nanoparticle-mediated delivery of AXL siRNA inhibits metastasis of ovarian and uterine cancer cells in mouse xenografts

D. Mutch, K. Fuh, S. Wickline, 2019, Scientific Reports.

Potential of cervical electrosurgical excision procedure for diagnosis and treatment of cervical intraepithelial neoplasia.

D. Mutch, J. Rader, H. Camel, 1995, Gynecologic Oncology.

Endometrial Tumor Immune Response: Predictive Biomarker of Response to Immunotherapy

D. Mutch, M. Mullen, 2019, Clinical Cancer Research.

Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol.

D. Mutch, S. Waggoner, J. Boggess, 2017, Gynecologic Oncology.

Dexamethasone used as an antiemetic in chemotherapy protocols inhibits natural cytotoxic (NC) cell activity

D. Mutch, M. Kao, C. Bethan Powell, 1990, Cancer.

Bevacizumab therapy in patients with recurrent uterine neoplasms.

D. Mutch, J. Rader, R. Gibb, 2007, Anticancer research.

Inhibition of protein synthesis enhances the lytic effects of tumor necrosis factor alpha and interferon gamma in cell lines derived from gynecological malignancies.

D. Mutch, M. Kao, J. Collins, 1991, Cancer immunology, immunotherapy : CII.

The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas

Nancy F. Hansen, J. Mullikin, N. Hansen, 2018, Cancer.

FIGO Update: Vancouver, Canada, October 2015.

D. Mutch, 2016, Gynecologic Oncology.

Getting the Message Out: RNA Interference of Human Papillomavirus

D. Mutch, J. Wright, 2007, Reproductive Sciences.

Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial carcinoma.

P. Grigsby, D. Mutch, J. Rader, 2007, International journal of radiation oncology, biology, physics.

Utility and cost-effectiveness of preoperative autologous blood donation in gynecologic and gynecologic oncology patients

D. Mutch, J. Rader, R. Gibb, 2002 .

Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy.

D. Mutch, S. Bhoola, W. Huh, 2005, Gynecologic Oncology.

Liquid-based cytology for the postirradiation surveillance of women with gynecologic malignancies.

D. Mutch, J. Rader, R. Gibb, 2003, Gynecologic oncology.

Correction: FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features

P. Pollock, S. Byron, P. Goodfellow, 2012, PLoS ONE.

Microsatellite instability, MLH1 promoter methylation, and loss of mismatch repair in endometrial cancer and concomitant atypical hyperplasia.

P. Goodfellow, D. Mutch, J. Rader, 2002, Gynecologic oncology.

Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer.

P. Grigsby, S. Mutic, D. Mutch, 2019, International journal of radiation oncology, biology, physics.

Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin.

D. Mutch, T. Herzog, H. Liapis, 2005, Gynecologic oncology.

Lack of effect of tumor size on the prognosis of carcinoma of the uterine cervix Stage IB and IIA treated with preoperative irradiation and surgery.

P. Grigsby, D. Mutch, J. Rader, 1999, International journal of radiation oncology, biology, physics.

Text-message-based behavioral weight loss for endometrial cancer survivors with obesity: A randomized controlled trial.

G. Colditz, D. Mutch, P. Thaker, 2021, Gynecologic oncology.

Differential Methylation Hybridization Array of Endometrial Cancers Reveals Two Novel Cancer-Specific Methylation Markers

P. Goodfellow, D. Mutch, T. Huang, 2007, Clinical Cancer Research.

Disparities in ovarian cancer care quality and survival according to race and socioeconomic status.

P. Roland, D. Mutch, W. Cliby, 2013, Journal of the National Cancer Institute.

Targeted metabolomic profiling of low and high grade serous epithelial ovarian cancer tissues: a pilot study

D. Mutch, B. Rosen, A. Yilmaz, 2018, Metabolomics.

AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS. DIAGNOSIS AND TREATMENT OF GESTATIONAL TROPHOBLASTIC DISEASE: ACOG PRACTICE BULLETIN NO. 53

D. Mutch, J. Soper, 2004 .

Update on Prognostic Markers for Endometrial Cancer

D. Mutch, P. Binder, 2014, Women's health.

Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 Trial.

Richard G. Moore, L. Brinton, D. Mutch, 2015, Journal of the National Cancer Institute.

Ovary, Fallopian Tube, and Primary Peritoneal Carcinoma

D. Mutch, P. Bhosale, R. Gibb, 2017 .

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.

E. Petricoin, D. Matei, M. Birrer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Risk of Lymph Node Metastasis With Positive Peritoneal Cytology in Endometrial Cancer

D. Mutch, A. Hagemann, M. Powell, 2013, International Journal of Gynecologic Cancer.

A phase I/II study of ruxolitinib with frontline neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer.

R. Burger, D. Mutch, C. Landen, 2022, Journal of Clinical Oncology.